賽生藥業(06600.HK)2021年淨利9.23億元 同比增加約22.5%
格隆匯3月24日丨賽生藥業(06600.HK)公吿,截至2021年12月31日止年度,收入約為人民幣25.18億元,較去年增長約31.3%,創過往四年的增長新高,乃受自有產品日達仙的強勁銷售及授權引入產品開始銷售所帶動;淨利潤約為人民幣9.23億元,較去年增加約22.5%;公司擁有人應占每股基本盈利約為人民幣1.42元,較去年同期增加約2.9%;公司擁有人應占每股攤薄盈利約為人民幣1.33元,較去年同期減少約1.5%;每股基本及攤薄盈利的變動幅度與淨利潤的增加幅度並不一致,此乃主要由於公司於2021年3月3日在聯交所主板上市時發行新股所致;董事會建議就截至2021年12月31日止年度派付末期股息每股0.35港元。
COVID-19疫情於各方面對全球造成深遠的影響,並加快多項趨勢,如藥物開發創新、數字化及醫療消費化。公司快速適應該等轉變,使公司擁有於2021年及後持續增長的優勢。公司實現快速開發潛在首創候選藥物,將互聯網醫院及新零售渠道融入創新"GTP"模式,並整合完善的增值服務以提升患者體驗。
憑藉公司的集成平台,公司已建立專注於高潛力治療領域的均衡產品組合,通過有效生命週期管理及創新GTP模式,以具有強大現金產生能力的上市產品為主導,並以具有同類首創╱同類最佳潛力的創新在研產品管線為支持,推動可持續的長期增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.